期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉非替尼治疗NSCLC脑膜转移的疗效观察 被引量：1

下载PDF
导出
摘要 目的分析并探讨吉非替尼治疗非小细胞肺癌(NSCLC)脑膜转移的疗效,不良反应和预后。方法回顾并分析我院收治的14例NSCLC患者的病历,14例患者均口服吉非替尼150mL/d,分析患者的病情发展情况,对所得数据进行汇总分析。结果对患者进行随访,评价治疗结果,其中,2(14%)例患者获CR,5(35%)例PR,ORR为49%,3(21%)例SD,DCR为70%,4例(29%)PD。患者的中位生存期(mOS)为11.4个月,中位无疾病进展生存期为(mPFS)8.2个月。结论根据分析,吉非替尼对治疗小细胞肺癌脑膜转移有较好的疗效,但也存在毒副作用,值得进行进一步的研究。
作者 李冬雷 李冬杰 王卫军
机构地区 保定市第二中心医院
出处 《中国医药指南》 2013年第26期409-410,共2页 Guide of China Medicine
关键词 吉非替尼 NSCLC 恶性肿瘤 脑膜转移
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献45

  • 1杨玲,李连弟,陈育德,D.M.Parkin.中国2000年及2005年恶性肿瘤发病死亡的估计与预测[J].中国卫生统计,2005,22(4):218-221. 被引量：336
  • 2Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA,2003,290(16): 2149-2158.
  • 3Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ,1995,311(7010): 899-909.
  • 4Therasse P, Arbuck SC-, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Ca
  • 5Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res,2002,8(11) : 3496-3502.
  • 6Cappuzzo F, Ardizzoni A, Soto-Parra H, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).Lung Cancer,2003,41(2) : 227-231.
  • 7Katakami N, Okazaki M, Kinose D, et al. A retrospective analysis of the outcome of patients (pts) in advanced recurrent adenocarcinoma of the lung who have received gefitinib after treatment of platinum-base regimen. Proc Am Soc Clin Oncol,2003,22: 666a.
  • 8Tamura K, Yamamoto N, Takeda K, et al. Am epidemiological survey for interstitial lung disease induced by gefitinib in patients with advanced non-small cell lung cancer. West Japan Thoracic Oncology Group (WJTOG). Eur J Cancer, 2003, 1 (5 Suppl) :S21.
  • 9Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors:results of a phase Ⅰ trial. J Clin Oncol,2002,20(9): 2240-225
  • 10Bernardo G, Cuzzoni Q, Strada MR, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase Ⅱ study. Cancer Invest,2002,20(3): 293-302.

共引文献57

同被引文献14

  • 1Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [ J]. CA Cancer J Clin, 2015, 65(1) : 5-29.
  • 2Song B, Zhan H, Bian Q, et al. Knockdown of CUIAB inhibits proliferation and promotes apoptosis of colorectal cancer cells through suppressing the Wnt/β-catenin signaling pathway[ J]. lnt J Clin Exp Pathol, 2015, 8 (9) : 10394-10402.
  • 3Qian Y, Yuan J, Hu H, et al. The CUL4B/AKT/β-catenin axis restricts the accumulation of myeloid-derived suppressor cells to prohibit the establishment of a tumor-permissive microenvironme- nt[J]. Cancer Res, 2015, 75(23):5070-5083.
  • 4Yang Y, Liu R, Qiu R, et al. CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylatio- n-based epigenetic silencing [ J ]. Oncogene, 2015, 34 ( 1 ) : 104 -118.
  • 5Lee J, Zhou P. Pathogenic role of the CRL4 ubiquitin ligase in human disease [ J/OL ]. Front Oncol, 2012 [ 2015-05-22 ]. http ://www. ncbi. nlm. nih. gov/pmc/articles/pmid/22649780.
  • 6Kerzendorfer C, Whibley A, Carpenter G, et al. Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent DNA breaks [J]. Hum Mol Genet. 2010, 19(7) :1324-1334.
  • 7Mok MT, Cheng AS. CUL4B: a novel epigenetic driver in Wnt/β-catenin-dependent hepatocarcinogenesis [ J]. J Pathol, 2015, 236(1) :1-4.
  • 8Yuan J, Han B, Hu H, et al. CUL4B activates Wnt/β-catenin signalling in hepatocellular carcinoma by repressing Wnt antago- nists[J]. J Pathol, 2015, 235(5):784-795.
  • 9Jiang T, Tang HM, Wu ZH, et al. Cullin 4B is a novel prognostic marker that correlates with colon cancer progression and pathogenesis[ J]. Med Oneol, 2013, 30(2): 534.
  • 10Chen Z, Shen BL, Fu QG, et al. CUL4B promotes proliferation and inhibits apoptosis of human osteosarcoma cells [ J ]. Oncol Rep, 2014, 32(5): 2047-2053.

引证文献1

二级引证文献2

中国医药指南
2013年 第26期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部